Clearance of interstitial fluid (ISF) and CSF (CLIC) group‐part of Vascular Professional Interest Area (PIA), updates in 2022‐2023. Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease: Opportunities for therapy

This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarchi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimer's & dementia 2024-02, Vol.20 (2), p.1421-1435
Hauptverfasser: Kelly, Louise, Brown, Christopher, Michalik, Daniel, Hawkes, Cheryl A., Aldea, Roxana, Agarwal, Nivedita, Salib, Rami, Alzetani, Aiman, Ethell, Douglas W, Counts, Scott E., Leon, Mony, Fossati, Silvia, Koronyo‐Hamaoui, Maya, Piazza, Fabrizio, Rich, Steven A., Wolters, Frank J., Snyder, Heather, Ismail, Ozama, Elahi, Fanny, Proulx, Steven T., Verma, Ajay, Wunderlich, Hilary, Haack, Mareike, Dodart, Jean Cosme, Mazer, Norman, Carare, Roxana O.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This editorial summarizes advances from the Clearance of Interstitial Fluid and Cerebrospinal Fluid (CLIC) group, within the Vascular Professional Interest Area (PIA) of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART). The overarching objectives of the CLIC group are to: (1) understand the age‐related physiology changes that underlie impaired clearance of interstitial fluid (ISF) and cerebrospinal fluid (CSF) (CLIC); (2) understand the cellular and molecular mechanisms underlying intramural periarterial drainage (IPAD) in the brain; (3) establish novel diagnostic tests for Alzheimer's disease (AD), cerebral amyloid angiopathy (CAA), retinal amyloid vasculopathy, amyloid‐related imaging abnormalities (ARIA) of spontaneous and iatrogenic CAA‐related inflammation (CAA‐ri), and vasomotion; and (4) establish novel therapies that facilitate IPAD to eliminate amyloid β (Aβ) from the aging brain and retina, to prevent or reduce AD and CAA pathology and ARIA side events associated with AD immunotherapy.
ISSN:1552-5260
1552-5279
1552-5279
DOI:10.1002/alz.13512